A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
R. J. Schilder, M. W. Sill, H. A. Lankes, M. A. Gold, R. S. Mannel, S. C. Modesitt, P. Hanjani, A. J. Bonebrake, A. K. Sood, A. K. Godwin, W. Hu, R. K. Alpaugh
Dive into the research topics of 'A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.